A postdoctoral position studying the genetics of prostate cancer survival is available in the Klein Lab at the Icahn School of Medicine at Mount Sinai (ISMMS) in New York City. The person hired for this position, which will be co-mentored by Dr. Robert Klein (Genetics) and Dr. Xiaoyu Song (Biostatistics), will conduct in silico genomic analyses aimed at identifying genes in which inherited genetic variation influences survival time in prostate cancer. The successful candidate will have a doctoral degree and experience in a related field such as biostatistics, bioinformatics, human or quantitative genetics, or epidemiology. Besides a competitive stipend, postdocs at Mount Sinai are eligible for a number of benefits including medical, dental, and vision coverage, along with a variety of life insurance and disability plans. ISMMS’ BeneFlex program allows you to tailor these options to suit your own needs. Individuals who are members of groups identified by the NIH as historically underrepresented in science are especially encouraged to apply. Interested indivdiuals should send their CV and a brief description of their research interest in this position to Dr. Klein at Robert.email@example.com.
About Icahn School of Medicine at Mount Sinai
At the Icahn School of Medicine at Mount Sinai, we are dramatically advancing the art and science of medical care through an atmosphere of intense collaborative learning, social concern, and scholarly inquiry.
We pursue innovative approaches to education, research and patient care, combining the best traditions of medicine with the principles and entrepreneurial thinking of a startup, to uncover novel insights about disease. Building this culture of innovation requires making large investments and taking a transformative approach to discovery, which means taking risks and disrupting the status quo. In this way, we are transforming the practice of medicine and reinventing medical research to produce radically better outcomes for patients.
As a leader in biomedical research, we have hired accomplished scientists and executives with startup experience and melded them with Mount Sinai’s doctors and researchers, spurring new levels of collaboration among our faculty. We are an engine of discovery, creating new treatments for the patients who need them the most, working in partnership with leading high-tech companies. We are on the threshold of a new era in precision medicine, and... our mission is to cure diseases once thought incurable, changing the lives of patients worldwide.
Our values are deeply ingrained in the School. When they opened the school’s doors in 1968, our founding trustees envisioned a new and progressive institution, embedded within the real-world environment of a working hospital. They called for the levels of passion, inquiry, dedication, knowledge, leadership, and innovation for which the School is renowned.
Today, we train nearly 2,000 students and postdoctoral fellows each year, with several thousand faculty members in numerous clinical and basic science departments, multidisciplinary institutes and centers. Our NIH funding is among the highest nationwide. We have built inspirational leadership, a comprehensive infrastructure, strategic affiliates, and a solid support system, as we train health care leaders for the 21st century amid the vibrant and diverse city of New York.